Chimerix to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences: the 9th Annual Needham Healthcare Conference, 9:00 AM ET, June 9, 2010, and the Jefferies 2010 Global Life Sciences Conference, 12:45 PM ET, June 11, 2010. The conferences are being held in New York City.
Mr. Moch will provide a corporate overview, including an update on the company's clinical-stage candidates, CMX001 and CMX157. CMX001 is an orally-available, broad-spectrum antiviral being developed for the treatment of dsDNA viral infections in immunocompromised patients. The compound is in Phase 1 and 2 clinical trials for the treatment of cytomegalovirus and BK virus. CMX157, a novel lipid conjugate of the drug tenofovir, was created to improve upon the efficacy and safety of the prodrug Viread®, the leading nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV patients. CMX157, which is in Phase 1 clinical trials, is being developed for its potential to reduce systemic toxicity and enable the development of one-pill once-a-day fixed dose anti-HIV combinations.
Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.
SOURCE Chimerix, Inc.